Compare DTSS & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTSS | BGLC |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | Malaysia |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 10.1M |
| IPO Year | 2015 | 2019 |
| Metric | DTSS | BGLC |
|---|---|---|
| Price | $0.92 | $2.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.7K | 10.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.42 | 45.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $71,616,820.00 | $9,510,646.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 198.70 | N/A |
| 52 Week Low | $0.64 | $0.23 |
| 52 Week High | $2.70 | $15.19 |
| Indicator | DTSS | BGLC |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 49.59 |
| Support Level | $0.81 | $2.57 |
| Resistance Level | $0.98 | $5.02 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 45.72 | 83.33 |
Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.